-
Company Insights
Innovation and Patenting activity of Goodrx Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Goodrx Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Profile
Goodrx Holdings Inc – Company Profile
Goodrx Holdings Inc (Goodrx) is a provider of price comparison platforms that tracks prescription drug prices and offers drug coupons. It provides pricing information, discount programs, payment guidance, alerts, and other related services. The company’s platform also provides access to medication savings programs, medical provider consultations and lab tests through its telehealth offerings, HeyDoctor and the GoodRx Telehealth Marketplace, and other healthcare-related content. Goodrx prescription offering provides price comparisons and negotiated prices on prescriptions. The company offers its services through...
Add to Basket -
Product Insights
Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Female Contraception Pipeline Drugs Market Report Overview Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and natural methods. The Female Contraception pipeline drugs market research report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Thematic Analysis
Tech, Media, and Telecom IPO Themes 2018 to 2021 – Thematic Research
2021 was the strongest year for tech, media, and telecom (TMT) IPOs since 2018 with $237 billion of IPO proceeds raised. 2021 was a record year for billion-dollar TMT IPOs, with 53 in total. Established themes like e-commerce, mobile, fintech, and cloud have seen the most successful IPOs over the last four years. Cloud, fintech, cybersecurity, mobile, and gaming IPOs have generated the highest investor returns in the TMT market since 20 18. The US was the biggest market for...
-
Analyst Opinions
Smart Pharma – Technology brings Unprecedented Opportunities
Increased R&D costs, regulatory hurdles, and the emergence of new diseases are enforcing pharmaceutical companies to rethink their aging business models. The highly regulated pharma is slowly adopting emerging technologies to improve every aspect of the value chain, from drug discovery tIncreased R&D costs, regulatory hurdles, and the emergence of new diseases are enforcing pharmaceutical companies to rethink their aging business models. The highly regulated pharma is gradually adopting emerging technologies to improve every aspect of the value chain, from...
-
Thematic Analysis
IPOs in the Global Technology, Media, and Telecoms Sector 2018 to 2020 and Beyond- Thematic Research
A detailed presentation analyzing the key themes driving IPOs in the tech, media, and telecom (TMT) sector. It includes a review of activity since January 2018 and a look ahead to IPOs planned for 2021.
-
Sector Analysis
Use of Telemedicine in the United States of America (USA) during the COVID-19 Pandemic
Prior to the COVID-19 pandemic, telemedicine had not reached its full potential in the US, with several barriers preventing its widespread uptake, including reimbursement and access issues, lack of awareness, resistance to change, preference for in-person care, and technical and connectivity issues. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies...